{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:42:47Z","timestamp":1777574567043,"version":"3.51.4"},"reference-count":18,"publisher":"ALUNA","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>Aim: improve the effectiveness of treatment for patients with COPD in the acute phase with clinical and laboratory manifestations of endogenous intoxication by including carbon or organosilicon sorbents in complex therapy.\nMaterials and Methods: To evaluate the effectiveness of enterosorption therapy in the complex treatment of patients with COPD in the acute phase with clinical and laboratory manifestations of endogenous intoxication, patients were divided into three groups according to severity. The first group consisted of 34 patients (21.9%) with mild bronchial obstruction (GOLD 1), the second group included 64 patients (41.3%) with moderate bronchial obstruction (GOLD 2), and the third group included 57 patients (36.8%) with severe bronchial obstruction (GOLD 3). The control group consisted of 20 healthy people aged 40 to 78 years. The following exclusion criteria were used: the presence of diabetes mellitus, acute coronary syndrome, previous myocardial infarction, rheumatological pathology, oncological and infectious diseases, acute inflammatory processes of any localization in patients.\nResults: COPD in the exacerbation phase is accompanied by clinical and laboratory manifestations of endotoxicosis, more pronounced in patients with severe broncho-obstruction. This is manifested by an increase in the content of endogenous intoxication indicators in blood serum (molecules of medium weight by 84% and 126% (p&lt;0.001) and erythrocyte intoxication index by 86% (p&lt;0.001)). There is a direct correlation of mean strength between the severity of the disease and the level of MSM254 and MSM280 (r=0.496 and r=0.557, p&lt;0.01) and weak strength \u2013 with an erythrocyte index of intoxication (r=0.253, p&lt;0.01). COPD in the exacerbation phase is accompanied by the activation of free radical processes, most pronounced in patients with severe broncho-obstruction, manifested by a probable increase in malondialdehyde \u2013 by 116% (p&lt;0.001) and a decrease in the activity of superoxide dismutase \u2013 by 59% (p&lt;0.01) compared to the control. There is a direct mean strength correlation between severity and malondialdehyde levels (r=0.486, p&lt;0.01) and inverse with serum superoxide dismutase (r=-0.500, p&lt;0.01). MDA content in blood serum increases, SOD activity decreases with increasing age of patients.\nConclusions: COPD exacerbation accompanied by clinical and laboratory manifestations of endogenous intoxication, namely increasing concentrations of malondialdehyde and superoxide dismutase activity decrease depending on the severity and age of bronchial patients. With the progression of the disease also increases the content of interleukin 1\u03b2 and 10, tumor necrosis factor \u03b1, circulating immune complexes, immunoglobulin E and reduced lysozyme activity in serum, in proportion to the increase in the severity of the disease. The use in treatment of 10-day course enterosorbtsiynoyi therapy using carbon (karbolaynu) or silicone (enterosgel) enterosorbent in treatment of patients with COPD exacerbation is accompanied by a decrease in clinical and laboratory manifestations of endotoxemia, such as cough, shortness of breath, discharge of phlegm, weakness and significant reduction of the average molecular weight and erythrocyte intoxication index, malondialdehyde, interleukins, immunoglobulin E and circulating immune complexes and increased activity of SOD and content of lysozyme in serum.<\/jats:p>","DOI":"10.36740\/merkur202602108","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:22:36Z","timestamp":1777404156000},"page":"151","source":"Crossref","is-referenced-by-count":0,"title":["Enterosorption therapy of chronic obstructive pulmonary disease against the background of endogenous intoxication"],"prefix":"10.36740","volume":"54","author":[{"given":"Larysa Ya.","family":"Fedoniuk","sequence":"first","affiliation":[{"name":"I.HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana V.","family":"Kucher","sequence":"additional","affiliation":[{"name":"I.HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena V.","family":"Lototska","sequence":"additional","affiliation":[{"name":"I.HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Al Wachami N, Guennouni M, Iderdar Y, Boumendil K, Arraji M, Mourajid Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health. 2024;24(1):297. doi:10.1186\/s12889-024-17686-9.","DOI":"10.1186\/s12889-024-17686-9"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. MacLeod M, Papi A, Contoli M, Beghe B, Celli BR, Wedzicha JA, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532-551. doi:10.1111\/resp.14041.","DOI":"10.1111\/resp.14041"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023;6(12):e2346598. doi:10.1001\/jamanetworkopen.2023.46598.","DOI":"10.1001\/jamanetworkopen.2023.46598"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants (Basel). 2022;11(5):965. doi:10.3390\/antiox11050965.","DOI":"10.3390\/antiox11050965"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Miklos Z, Horvath I. The role of oxidative stress and antioxidants in cardiovascular comorbidities in COPD. Antioxidants (Basel). 2023;12(6):1196. doi:10.3390\/antiox12061196.","DOI":"10.3390\/antiox12061196"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Fatullayeva S, Tagiyev D, Zeynalov N. A review on enterosorbents and their application in clinical practice: removal of toxic metals. Colloids Interface Sci Commun. 2021;45:100545. doi:10.1016\/j.colcom.2021.100545.","DOI":"10.1016\/j.colcom.2021.100545"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Shichkin VP, Kurchenko OV, Okhotnikova EN, Chopyak VV, Delfino DV. Enterosorbents in complex therapy of food allergies: a focus on digestive disorders and systemic toxicity in children. Front Immunol. 2023;14:1210481. doi:10.3389\/fimmu.2023.1210481.","DOI":"10.3389\/fimmu.2023.1210481"},{"key":"ref7","unstructured":"8. Lykholat O, Pavlenko O. COPD as metabolic pathology: problem of common oxidative stress, endotoxicities and neurotoxicity. Rom J Diabetes Nutr Metab Dis. 2023;30(3):316-323. doi:10.46389\/rjd-2023-0303."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Aggarwal T, Wadhwa R, Thapliyal N, Sharma K, Rani V, Maurya PK. Oxidative, inflammatory, genetic, and epigenetic biomarkers associated with chronic obstructive pulmonary disorder. J Cell Physiol. 2019;234(3):2067-2082. doi:10.1002\/jcp.27110.","DOI":"10.1002\/jcp.27181"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. In: Molecular Basis of Oxidative Stress: Chemistry, Toxicology, Disease Pathogenesis, Diagnosis, and Therapeutics. London: Academic Press; 2025. p. 381-393.","DOI":"10.1002\/9781119790419.ch15"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Nambiar S, Bong How S, Gummer J, Trengove R, Moodley Y. Metabolomics in chronic lung diseases. Respirology. 2020;25(2):139-148. doi:10.1111\/resp.13687.","DOI":"10.1111\/resp.13530"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Antunes MA, Lopes-Pacheco M, Rocco PRM. Oxidative stress-derived mitochondrial dysfunction in chronic obstructive pulmonary disease: a concise review. Oxid Med Cell Longev. 2021;2021:6644002. doi:10.1155\/2021\/6644002.","DOI":"10.1155\/2021\/6644002"},{"key":"ref12","unstructured":"13. Salman RA. Clinical biochemistry in the diagnosis of chronic pulmonary diseases: identifying biomarkers and innovative treatment strategies [Internet]. Available from: https:\/\/core.ac.uk\/download\/pdf\/622173787.pdf"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Hussein FG, Mohammed RS, Khattab RA, Al-Sharawy LA. Serum interleukin-6 in chronic obstructive pulmonary disease patients and its relation to severity and acute exacerbation. Egypt J Bronchol. 2022;16(1):1. doi:10.1186\/s43168-022-00128-0.","DOI":"10.1186\/s43168-022-00115-z"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Zinellu E, Zinellu A, Fois AG, Pau MC, Scano V, Piras B, et al. Oxidative stress biomarkers in chronic obstructive pulmonary disease exacerbations: a systematic review. Antioxidants (Basel). 2021;10(5):710. doi:10.3390\/antiox10050710.","DOI":"10.3390\/antiox10050710"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Kucher SV, Lototska OV. Inclusion of enterosorbents in anti-inflammatory therapy improve treatment effectiveness in COPD patients during exacerbations. Ukr Biochem J. 2021;93(2):107-114. doi:10.15407\/ubj93.02.107.","DOI":"10.15407\/ubj93.02.107"},{"key":"ref16","unstructured":"17. Sabirova RA, Aslanova AK. Molecular and cellular mechanisms of action of sorbents used in medicine. Cent Asian J Med. 2022;(3):231-247."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Mikhalovsky S, Voytko A, Demchenko V, Demchenko P. Enterosorption in the treatment of heavy metal poisoning. Chem J Mold. 2021;16(2):9-27. doi:10.19261\/cjm.2021.857.","DOI":"10.19261\/cjm.2021.852"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:22:48Z","timestamp":1777404168000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek20026i2net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202602108","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}